Doxorubicin

• Description:

  Doxorubicin (Hydroxydaunorubicin), a broad-spectrum anthracycline antibiotic with cytotoxic properties, is an anti-cancer chemotherapy agent. Doxorubicin has fluorescence properties. Doxorubicin inhibits topoisomerase II with an IC50 of 2.67 μM, thus stopping DNA replication. Doxorubicin reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin induces apoptosis and autophagy[1][2]. Doxorubicin inhibits human DNA topoisomerase I with an IC50 of 0.8 μM[3].

• Product Name Alternative:

  Hydroxydaunorubicin

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  ADC Payload; AMPK; Antibiotic; Apoptosis; Autophagy; Bacterial; Fluorescent Dye; HBV; HIV; Mitophagy; Topoisomerase

• Type:

  Natural Products

• Related Pathways:

  Antibody-drug Conjugate/ADC Related; Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; Others; PI3K/Akt/mTOR

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer; Infection

• Assay Protocol:

  https://www.medchemexpress.com/Doxorubicin.html

• Purity:

  98.60

• Solubility:

  10 mM in DMSO

• Smiles:

  COC1=C2C(C(C(C(O)=C(C[C@](C(CO)=O)(O)C[C@@H]3O[C@@]4([H])C[C@H](N)[C@H](O)[C@H](C)O4)C3=C5O)=C5C2=O)=O)=CC=C1

• Molecular Formula:

  C27H29NO11

• Molecular Weight:

  543.52

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Nitiss JL, et al. Targeting DNA topoisomerase II in cancer chemotherapy.Nat Rev Cancer. 2009 May;9 (5) :338-50.|[2]Rhee HK, et al. Synthesis, cytotoxicity, and DNA topoisomerase II inhibitory activity of benzofuroquinolinediones. Bioorg Med Chem. 2007 Feb 15;15 (4) :1651-8.|[3]Foglesong PD, et al. Doxorubicin inhibits human DNA topoisomerase I. Cancer Chemother Pharmacol. 1992;30 (2) :123-5.|[4]Sadeghi-Aliabadi H, et al. Cytotoxic evaluation of doxorubicin in combination with simvastatin against human cancer cells. Res Pharm Sci. 2010 Jul;5 (2) :127-33.|[5]El-Zawahry A, et al. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancerxenografts. BMC Cancer. 2005 Jan 7;5:2.|[6]Hayward R, et al. Doxorubicin cardiotoxicity in the rat: an in vivo characterization. J Am Assoc Lab Anim Sci. 2007 Jul;46 (4) :20-32.|[7]Johansson S, et al. Elimination of HIV-1 infection by treatment with a doxorubicin-conjugated anti-envelope antibody. AIDS. 2006;20 (15) :1911-1915.|[8]Koda LY, Van der Kooy D. Doxorubicin: a fluorescent neurotoxin retrogradely transported in the central nervous system. Neurosci Lett. 1983 Mar 28;36 (1) :1-8. doi: 10.1016/0304-3940 (83) 90476-7. PMID: 6190113. 9|[9]Mirza A Z, Shamshad H. Preparation and characterization of doxorubicin functionalized gold nanoparticles[J]. European journal of medicinal chemistry, 2011, 46 (5) : 1857-1860.|[10]Kauffman MK, Kauffman ME, Zhu H, Jia Z, Li YR. Fluorescence-Based Assays for Measuring Doxorubicin in Biological Systems. React Oxyg Species (Apex) . 2016;2 (6) :432-439. doi: 10.20455/ros.2016.873. PMID: 29707647; PMCID: PMC5921830.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture and light)

• Scientific Category:

  Natural Products

• Clinical Information:

  Launched

• Isoform:

  Daunorubicins/Doxorubicins; HIV-1; Topo I; Topo II

• Citation 01:

  ACS Omega. 2019 Jul 11;4 (7) :12036-12042.|Acta Biomater. 2020 Jun;109:229-243.|Acta Biomater. 2024 Apr 15:179:340-353.|Adv Healthc Mater. 2019 Sep;8 (18) :e1900543.|Adv Sci (Weinh) . 2022 May;9 (15) :e2105894.|Adv Sci (Weinh) . 2022 Oct;9 (30) :e2201210.|Adv Sci (Weinh) . 2023 May;10 (15) :e2206007.|Adv Sci (Weinh) . 2025 Jan 31:e2408845.|Am J Physiol Cell Physiol. 2024 Jan 1;326 (1) :C161-C176.|Anal Chem. 2023 Apr 11;95 (14) :6191.|Antioxid Redox Signal. 2024 Apr;40 (10-12) :598-615.|Artif Cells Nanomed Biotechnol. 2023 Dec;51 (1) :120-130.|Asian J Pharm Sci. 2024 Feb;19 (1) :100884.|Biochem Biophys Rep. 2024 Jan 14:37:101639.|Biochem Biophys Res Commun. 2019 Sep 24;517 (3) :538-544.|Biochem Biophys Res Commun. 2020 Jan 15;521 (3) :596-602.|Biochem Biophys Res Commun. 2024 Jan 1:690:149244.|Biochem Biophys Res Commun. 2024 Jan 8:691:149314.|Biochem Biophys Res Commun. 2024 Mar 12:700:149582.|Biochem Pharmacol. 2020 Apr;174:113795.|Biochem Pharmacol. 2020 May;175:113888.|Biochem Pharmacol. 2023 Oct:216:115769.|Biochem Pharmacol. 2024 May:223:116142.|Biochem Pharmacol. 2020 May;175:113856.|Biochim Biophys Acta Mol Cell Res. 2023 Feb;1870 (2) :119409.|Biochim Biophys Acta Mol Cell Res. 2023 Feb;1870 (2) :119411.|Biofabrication. 2022 Apr 13;14 (3) .|Biomacromolecules. 2023 Feb 13;24 (2) :849-857.|Biomaterials. 2023 Oct:301:122236.|Biomed Pharmacother. 2020 Mar;123:109803.|Biomed Pharmacother. 2023 Dec:168:115654.|Biomed Pharmacother. 2023 Jan:157:114087.|Biomed Pharmacother. 2023 Jun:162:114691.|Biomed Pharmacother. 2023 Jun:162:114733.|Biomolecules. 2022 Feb 12;12 (2) :299.|Bioorg Chem. 2022 Dec:129:106206.|bioRxiv. 2023 Apr 14.|bioRxiv. 2023 Feb 27:2023.02.27.530263.|bioRxiv. 2023 Sep 5.|bioRxiv. 2025 Jun 26.|BMC Cancer. 2019 Jun 18;19 (1) :602. |Br J Pharmacol. 2022 Jul;179 (13) :3346-3362.|Breast Cancer Res Treat. 2023 Jul;200 (2) :193-201.|Breast Cancer Res. 2023 Oct 4;25 (1) :115.|Breast Cancer Res. 2024 Mar 19;26 (1) :48.|Cancer Biol Ther. 2024 Dec 31;25 (1) :2403197.|Cancer Cell Int. 2019 Jul 12:19:179.|Cancer Discov. 2025 Jun 16.|Cancer Lett. 2023 Feb 1:554:216028.|Cancer Res. 2025 May 14.|Cancers (Basel) . 2022 Jun 22;14 (13) :3068.|Cancers (Basel) . 2023 Feb 1;15 (3) :930.|Carcinogenesis. 2022 Dec 25;43 (11) :1071-1082.|Cell Biochem Funct. 2022 Jun;40 (4) :403-416.|Cell Biosci. 2022 Jan 6;12 (1) :6.|Cell Chem Biol. 2020 Nov 19;27 (11) :1359-1370.e8.|Cell Chem Biol. 2024 Jul 9:S2451-9456 (24) 00273-3.|Cell Commun Signal. 2024 Jun 13;22 (1) :325.|Cell Death Differ. 2022 Oct;29 (10) :1982-1995.|Cell Death Dis. 2019 Nov 25;10 (12) :887. |Cell Death Dis. 2022 Apr 5;13 (4) :305.|Cell Death Dis. 2024 Jan 18;15 (1) :66.|Cell Death Dis. 2025 Nov 24;16 (1) :856.|Cell Death Dis. 2019 Sep 11;10 (9) :668.|Cell Mol Neurobiol. 2023 Jul;43 (5) :2179-2202.|Cell Physiol Biochem. 2017;42 (3) :965-973.|Cell Rep. 2025 Mar 25;44 (4) :115466.|Cell Res. 2018 Dec;28 (12) :1171-1185. |Cell Signal. 2017 Aug:36:108-116.|Cell Signal. 2023 Jul:107:110655.|Cell Stress Chaperones. 2023 Jan;28 (1) :91-103.|Chem Biol Interact. 2024 Apr 1:392:110904.|Chem Eng J. 15 October 2022, 137110.|Chronic Diseases Prevention Review. 2019 Feb.|Clin Cancer Res. 2020 Apr 15;26 (8) :2011-2021. |Clin Cancer Res. 2025 Nov 20.|Clin Exp Pharmacol Physiol. 2023 Nov;50 (11) :867-877.|Clin Transl Med. 2024 Feb;14 (2) :e1586.|Clin Transl Oncol. 2023 Aug;25 (8) :2408-2418.|Commun Biol. 2022 Nov 26;5 (1) :1295.|Comput Biol Med. 2024 Jul 18:179:108901.|Drug Deliv. 2025 Dec 31;32 (1) :2585612.|EMBO Rep. 2025 Aug;26 (16) :4100-4123.|Eur J Med Chem. 2023 Oct 5:258:115602.|Eur J Med Chem. 2024 Jan 15:264:115975.|Eur J Nucl Med Mol Imaging. 2024 Jul;51 (8) :2204-2215.|Eur J Pharm Sci. 2023 Sep 1:188:106472.|Eur J Pharmacol. 2024 Jul 5:974:176538.|Evid Based Complement Alternat Med. 2022 Sep 28;2022:7760945.|Exp Ther Med. 2023 May 16;26 (1) :325.|FASEB J. 2022 Sep;36 (9) :e22495.|FASEB J. 2023 Dec;37 (12) :e23284.|FASEB J. 2023 Jun;37 (6) :e22982.|Food Funct. 2022 Feb 21;13 (4) :2200-2215.|Food Funct. 2022 Sep 22;13 (18) :9576-9588.|Free Radic Biol Med. 2022 Nov 20;193 (Pt 1) :108-121.|Free Radic Biol Med. 2024 Jun 18:S0891-5849 (24) 00526-4.|Front Cell Dev Biol. 2021 May 31:9:661602.|Front Immunol. 2020 May 5;11:802.|Front Oncol. 2020 Mar 13;10:308.|Gels. 2022 Apr 12;8 (4) :237.|Gels. 2022 Sep 16;8 (9) :594.|Heliyon. 2024 Jun 28;10 (13) :e33835.|IEEE Access. 2023 May 31.|Infect Immun. 2019 Dec 17;88 (1) :e00697-19.|Int Immunopharmacol. 2023 Jan:114:109450.|Int Immunopharmacol. 2024 Aug 24:141:113010.|Int J Biol Sci. 2022 Apr 11;18 (7) :2882-2897.|Int J Biol Sci. 2022 Feb 7;18 (4) :1724-1736.|Int J Clin Exp Pathol. 2017;10 (3) :3033-3042.|Int J Mol Sci. 2023 Jan 7;24 (2) :1194.|Int J Mol Sci. 2023 Oct 20;24 (20) :15405.|Int J Nanomedicine. 2017 Mar 16:12:2081-2108.|Int J Oncol. 2022 Dec;61 (6) :148.|Int J Oncol. 2026 Jan;68 (1) :10.|International Journal of Biology and Life Sciences. 2023 May 22.|iScience. 2022 Sep 6;25 (10) :105064.|iScience. 2022 Sep 6;25 (10) :105081.|iScience. 2023 Oct 19;26 (11) :108272.|J Agric Food Chem. 2022 Jul 13;70 (27) :8326-8337.|J Cell Mol Med. 2019 Sep;23 (9) :6034-6047.|J Cell Mol Med. 2023 Aug;27 (16) :2385-2397.|J Clin Invest. 2018 Jan 2;128 (1) :483-499. |J Clin Invest. 2024 Mar 7;134 (10) :e172716.|J Drug Target. 2020 Feb;28 (2) :186-194.|J Electroanal Chem. 2023 Sep 16, 117808.|J Environ Chem Eng. February 2022, 107078.|J Enzyme Inhib Med Chem. 2019 Dec;34 (1) :117-123. |J Ethnopharmacol. 2020 Jul 15;257:112789.|J Exp Clin Cancer Res. 2018 Sep 19;37 (1) :232. |J Exp Clin Cancer Res. 2019 Aug 14;38 (1) :353. |J Food Biochem. 2022 Feb;46 (2) :e14065.|J Immunol. 2022 Dec 1;209 (11) :2181-2191.|J Med Chem. 2024 Apr 11;67 (7) :5924-5934.|J Med Virol. 2019 Oct;91 (10) :1818-1829.|J Nanobiotechnology. 2023 Aug 26;21 (1) :297.|J Nanobiotechnology. 2024 Mar 26;22 (1) :132.|J Nanobiotechnology. 2024 Mar 3;22 (1) :89.|J Nat Prod. 2020 Feb 28;83 (2) :516-523.|J Pharm Biomed Anal. 2024 Jun 15:243:116097.|J Photochem Photobiol B. 2023 Feb:239:112642.|J Toxicol Sci. 2023;48 (8) :469-479.|J Transl Med. 2023 Jan 9;21 (1) :9.|J Transl Med. 2023 Nov 17;21 (1) :823.|JCI Insight. 2022 Oct 18; e156485.|Life. 2022 Sep 2;12 (9) :1369.|Mar Drugs. 2022 Sep 21;20 (10) :591.|Mater Today Bio. 2025 Oct 23.|Mil Med Res. 2021 Dec 9;8 (1) :63.|Mol Biol Rep. 2023 Jan;50 (1) :507-516.|Mol Med Rep. 2020 Apr;21 (4) :1739-1748.|Mol Med Rep. 2020 Jul;22 (1) :67-76.|Mol Med Rep. 2023 Jan;27 (1) :17.|Mol Ther. 2023 May 3;31 (5) :1468-1479.|Molecules. 2020 Feb 14;25 (4) :836.|Nano Today. 2023 Aug, 51, 101898.|Nanomaterials. 2022 Dec 17;12 (24) :4478.|Nat Commun. 2019 Dec 2;10 (1) :5492. |Nat Commun. 2025 May 30;16 (1) :5006.|Nucleic Acids Res. 2018 Apr 20;46 (7) :3284-3297.|Nutrients. 2022 Sep 27;14 (19) :4017.|Oncogenesis. 2023 Jun 24;12 (1) :34.|Oncol Lett. 2020 Jul;20 (1) :145-154.|Oncol Lett. 2023 Aug 30;26 (4) :447.|Opt Express. 2021 Apr 12;29 (8) :11976-11986.|Org Chem Front. 11 Feb 2022.|Patent. US20230145200A1.|PeerJ. 2023 May 18:11:e15315.|Pharmaceutics. 2019 May 27;11 (5) :247.|Pharmaceutics. 2023 Oct 28;15 (11) :2550.|Pharmacogn Mag. 2023 Apr 14.|Pharmacol Res. 2022 Apr:178:106186.|Phytochemistry. 2022 Jul;199:113172.|Phytomedicine. 2022 May:99:154027.|Phytomedicine. 2023 Nov:120:155074.|Phytomedicine. 2025 Sep 25:148:157302.|Phytother Res. 2023 Dec;37 (12) :5854-5870.|Plasma Process Polym. 2021 Feb 12.|PLoS One. 2023 Jul 27;18 (7) :e0288422.|Redox Biol. 2022 Feb:49:102219.|Redox Biol. 2022 Jun;52:102310.|Redox Biol. 2024 Jun:72:103129.|Res Sq. 2024 Aug 11.|Research (Wash D C) . 2025 Jun 3:8:0718.|Research Square Preprint. 2021 Apr.|Research Square Preprint. 2021 Aug.|Research Square Preprint. 2022 Jun.|Research Square Preprint. 2023 Jun 16.|Research Square Print. November 29th, 2022.|RSC Adv. 2022 Oct 3;12 (43) :28104-28112.|RSC Med Chem. 2023 Dec 7;15 (2) :506-518.|Sci Rep. 2025 Nov 17;15 (1) :40072.|Sci Rep. 2019 Oct 22;9 (1) :15099. |Sci Rep. 2019 Oct 23;9 (1) :15172. |Small Methods. 2022 Mar;6 (3) :e2101391.|SSRN. 2019 Nov.|Talanta. 2024 Jul 1:274:125987.|Theranostics. 2019 Jan 24;9 (3) :761-777.|Theranostics. 2020 Jul 25;10 (21) :9477-9494. |Tissue Cell. 2023 Jun:82:102073.|Toxicol Appl Pharmacol. 2022 Oct 1:452:116179.|Toxics. 2023 Nov 12;11 (11) :925.|Toxins. 2023 Mar 25;15 (4) :242.|Trop J Pharm Res. 2022; 21 (12) : 2541-2548.|ACS Appl Bio Mater. 2025 Jul 21;8 (7) :6055-6065.|ACS Appl Mater Interfaces. 2020 Oct 21;12 (42) :47330-47341.|ACS Appl Mater Interfaces. 2022 Sep 7;14 (35) :39819-39829.|ACS Appl Mater Interfaces. 2024 Dec 18;16 (50) :69679-69689.|ACS Appl Mater Interfaces. 2025 Oct 22;17 (42) :57903-57918.|ACS Biomater Sci Eng. 2025 May 12;11 (5) :2727-2738.|ACS Biomater Sci Eng. 2025 Oct 13;11 (10) :5991-6003.|ACS Nano. 2020 Nov 24;14 (11) :15904-15918.|ACS Nano. 2024 Nov 12;18 (45) :31569-31585.|ACS Omega. 2025 Oct 29;10 (44) :52562–52575.|Acta Biomater. 2024 Dec 19:S1742-7061 (24) 00738-4.|Acta Biomater. 2025 Aug 27:S1742-7061 (25) 00640-3.|Acta Pharm Sin B. 2025 May;15 (5) :2545-2558.|Acta Pharmacol Sin. 2023 Oct;44 (10) :2004-2018.|Acta Pharmacol Sin. 2024 Oct;45 (10) :2174-2185.|Acta Pharmacol Sin. 2025 Sep 8.|Adv Funct Mater. 10 October 2021.|Adv Funct Mater. 23 October 2021.|Adv Healthc Mater. 2020 Nov;9 (22) :e2001633.|Adv Healthc Mater. 2021 Nov;10 (21) :e2101222.|Adv Healthc Mater. 2025 Jan;14 (3) :e2401887.|Adv Healthc Mater. 2025 Jul 14:e2502649.|Adv Mater. 2025 Aug 29:e05714.|Adv Mater. 2025 Oct 10:e05951.|Adv Sci (Weinh) . 2020 Sep 28;7 (21) :2001364.|Adv Sci (Weinh) . 2025 Aug 11:e11081.|Adv Sci (Weinh) . 2025 Jun 10:e02726.|Adv Sci (Weinh) . 2025 Mar;12 (12) :e2412017.|Adv Sci (Weinh) . 2025 Nov 9:e15349.|Adv Ther (Weinh) . 2021 Apr 14.|Aging Cell. 2025 Apr 10:e70065.|Am J Cancer Res. 2021 Apr 15;11 (4) :1428-1445.|Am J Physiol Cell Physiol. 2024 Aug 1;327 (2) :C254-C269.|Am J Transl Res. 2021 Sep 15;13 (9) :10112-10126.|Am J Transl Res. 2025 Sep 15;17 (9) :6960-6974. |Anal Chem. 2025 Jul 29;97 (29) :15753-15761.|Anal Chim Acta. 2024 Jan 25:1287:342110.|Angiogenesis. 2021 May;24 (2) :327-344.|Ann Transl Med. 2020 Dec;8 (23) :1570.|Anticancer Drugs. 2022 Mar 1;33 (3) :308-319.|Antioxid Redox Signal. 2025 Jan;42 (1-3) :115-132.|Antioxid Redox Signal. 2025 Mar;42 (7-9) :393-407.|Arab J Chem. July 2022, 103934.|Authorea. 2025 Mar 28.|Autophagy. 2021 Dec;17 (12) :3976-3991.|Autophagy. 2022 Aug;18 (8) :1879-1897.|BIO Web of Conferences. 2025.|Bioact Mater. 2024 May 11:38:384-398.|Biochem Biophys Res Commun. 2019 Dec 10;520 (3) :544-550.|Biochem Biophys Res Commun. 2020 Dec 10;533 (3) :304-312.|Biochem Biophys Res Commun. 2024 Aug 19:739:150568.|Biochem Biophys Res Commun. 2024 Jan 8:691:149314.|Biochem Pharmacol. 2025 Aug 22;242 (Pt 1) :117277.|Biochem Pharmacol. 2026 Jan;243 (Pt 1) :117484.|Bioconjug Chem. 2025 Feb 19;36 (2) :190-202.|Bioengineered. 2022 Apr;13 (4) :9467-9481.|Biol Direct. 2023 Oct 9;18 (1) :63.|Biol Proced Online. 2025 Jun 16;27 (1) :21.|Biomacromolecules. 2022 Nov 14;23 (11) :4586-4596.|Biomacromolecules. 2025 Feb 10;26 (2) :1032-1043.|Biomater Adv. 2022 Nov:142:213161.|Biomed Pharmacother. 2020 Oct;130:110534.|Biomed Pharmacother. 2021 Aug:140:111779.|Biomed Pharmacother. 2021 Jun:138:111531.|Biomed Pharmacother. 2021 May:137:111308.|Biomed Pharmacother. 2021 May;137:111378.|Biomed Pharmacother. 2024 Apr:173:116353.|Biomed Pharmacother. 2024 Jul 19:178:117167.|Biomed Pharmacother. 2024 Nov:180:117535.|Bioorg Chem. 2025 Apr 22:160:108508.|bioRxiv. 2020 Jun.|bioRxiv. 2023 Feb 7.|bioRxiv. 2023 Jan 13.|bioRxiv. 2023 May 12.|bioRxiv. 2024 Aug 2:2024.08.02.606061.|bioRxiv. 2024 Jul 22:2023.09.14.557413.|bioRxiv. 2024 May 15.|bioRxiv. 2024 Nov 6:2024.11.04.621884.|bioRxiv. 2024 September 19.|bioRxiv. 2025 Aug 19.|bioRxiv. 2025 Aug 27.|bioRxiv. 2025 February 22.|bioRxiv. 2025 Jul 29.|bioRxiv. 2025 June 07.|bioRxiv. 2025 Oct 15.|bioRxiv. 2025 Sep 21.|bioRxiv. 2025 Sep 9:2025.09.04.674312.|Blood Sci. 2024 Jul 10;6 (3) :e00192.|BMC Cancer. 2025 Jan 7;25 (1) :24.|Bone Res. 2025 Jun 3;13 (1) :58.|Br J Pharmacol. 2024 Nov;181 (21) :4195-4213.|Br J Pharmacol. 2025 Jun;182 (11) :2409-2425.|Braz J Med Biol Res. 2024 Jul 1:57:e13357.|Breast Cancer Res Treat. 2021 Sep;189 (2) :347-361.|Cancer Biol Med. 2021 Feb 15; 18 (1) : 184-198.|Cancer Biol Med. 2021 Feb.|Cancer Cell Int. 2024 Dec 26;24 (1) :430.|Cancer Commun (Lond) . 2024 Apr;44 (4) :469-490.|Cancer Discov. 2024 Jul 1;14 (7) :1302-1323.|Cancer Immunol Immunother. 2024 Jul 2;73 (9) :177.|Cancer Lett. 2021 Nov 1:520:361-373.|Cancer Lett. 2022 Jun 28;536:215651.|Cancer Sci. 2022 Jun;113 (6) :2008-2021.|Cancer Sci. 2025 Jul;116 (7) :2020-2031.|Cancers (Basel) . 2021 Jul 2;13 (13) :3323.|Cancers (Basel) . 2022 Jan 28;14 (3) :683.|Cardiovasc Diabetol. 2025 Nov 8;24 (1) :427.|Cell Biol Toxicol. 2024 Dec 21;41 (1) :15.|Cell Biomater. 2025 Jul 22.|Cell Death Differ. 2022 May;29 (5) :988-1003.|Cell Death Dis. 2020 Sep 15;11 (9) :756.|Cell Death Dis. 2022 Apr 5;13 (4) :305.|Cell Death Dis. 2022 Aug 24;13 (8) :731.|Cell Death Dis. 2024 Jul 31;15 (7) :545.|Cell Death Dis. 2024 May 20;15 (5) :349.|Cell Death Dis. 2025 Apr 11;16 (1) :276.|Cell Death Dis. 2025 Mar 19;16 (1) :185.|Cell Death Discov. 2021 Aug 5;7 (1) :204.|Cell Death Discov. 2025 Mar 6;11 (1) :89.|Cell Metab. 2022 Mar 1;34 (3) :424-440.e7.|Cell Rep Med. 2024 May 29:101592.|Cell Rep Med. 2025 Apr 2:102053.|Cell Rep. 2021 Aug 24;36 (8) :109568.|Cell Rep. 2023 Jan 31;42 (1) :111916.|Cell Rep. 2023 Mar 20;42 (3) :112275.|Cell Rep. 2024 Dec 21;44 (1) :115094.|Cell Rep. 2025 Jul 29;44 (8) :116079.|Cell Stem Cell. 2021 Dec 2;28 (12) :2076-2089.e7.|Cell. 2024 Apr 25;187 (9) :2288-2304.e27.|Cell. 2024 Dec 26;187 (26) :7637-7654.e29.|Cells. 2022 Aug 25;11 (17) :2642.|Cells. 2022 Dec 29;12 (1) :145.|Chem Biodivers. 2022 Oct;19 (10) :e202200489.|Chem Biol Interact. 2024 Jul 31:400:111179.|Chem Eng J. 2020, 127874.|Chin Med J (Engl) . 2025 Aug 20.|China Biotechnology. 2017, 37 (4) : 68-75.|Circ Heart Fail. 2021 Oct;14 (10) :e008220. |Clin Transl Med. 2025 May;15 (5) :e70336.|Colloid Interface Sci Commun. 2019 Jan:28:69-74.|Colloids Surf B Biointerfaces. 2018 Nov 1:171:176-185.|Colloids Surf B Biointerfaces. 2019 Jan 1:173:27-35.|Colloids Surf B Biointerfaces. 2021 Sep:205:111839.|Colloids Surf B Biointerfaces. 2024 Aug 5:244:114141.|Colloids Surf B Biointerfaces. 2024 May 3:239:113937.|Commun Biol. 2025 Jun 7;8 (1) :892.|Commun Biol. 2025 May 30;8 (1) :829.|Curr Med Sci. 2025 May 5.|Department of Pharmaceutical Sciences, University of Toronto. 2019 Oct.|Dev Cell. 2018 Sep 24;46 (6) :681-695.e5.|Discov Oncol. 2025 Apr 9;16 (1) :499.|Discov Oncol. 2025 Sep 24;16 (1) :1700.|DNA Repair. 2022 Jun:114:103319.|Drug Deliv Transl Res. 2023 Oct;13 (10) :2520-2532.|Drug Des Devel Ther. 2025 Feb 15:19:1067-1081.|Drug Des Devel Ther. 2025 Jul 12:19:5993-6008.|Drug Resist Updat. 2024 Sep 12:77:101151.|EBioMedicine. 2021 Jul;69:103456.|Elife. 2022 May 3;11:e69255.|Eur Heart J Open. 2023 Oct 9;3 (5) :oead104.|Eur J Med Chem. 2024 Nov 26:283:117108.|Eur J Med Res. 2025 Aug 4;30 (1) :704.|Eur J Pharm Biopharm. 2018 Aug:129:88-103.|Eur J Pharmacol. 2024 Jul 30:980:176865.|Eur J Pharmacol. 2025 Dec 5:1008:178303.|Exp Cell Res. 2025 May 28:114613.|Exp Cell Res. 2025 Sep 15;452 (1) :114754.|Expert Opin Drug Deliv. 2021 Jul;18 (7) :991-1004.|FEBS J. 2025 Jun 1.|FEBS Open Bio. 2022 Jan;12 (1) :221-230.|Food Biosci. 2025 Jan.|Food Biosci. 2025 Jun.|Food Sci Nutr. 2025 Nov 17;13 (11) :e71212.|Free Radic Biol Med. 2019 Jan:130:557-567.|Free Radic Biol Med. 2021 Feb 1;163:141-152.|Free Radic Biol Med. 2021 Feb 20:164:85-95.|Free Radic Biol Med. 2023 Aug 1:204:38-53.|Free Radic Biol Med. 2024 Aug 5:S0891-5849 (24) 00587-2.|Free Radic Biol Med. 2025 Oct:238:507-521.|Front Cell Dev Biol. 2021 Dec 24;9:781792.|Front Endocrinol. 2018 Mar 22:9:120.|Front Med. 2022 Apr 14:9:848938.|Front Oncol. 2024 Jul 19:14:1440650.|Future Med Chem. 2025 Dec;17 (24) :2927-2943.|Genes Genomics. 2024 Dec;46 (12) :1445-1460.|Geroscience. 2025 Jul 1.|Harvard Medical School LINCS LIBRARY|Health Technol (Berl) . 2025 Apr 23.|Heidelberg University. 2024.|Heliyon. 2023 Jul 15;9 (7) :e18318.|Heliyon. 2024 May 29;10 (11) :e32015.|Hepatology. 2020 May;71 (5) :1660-1677. |Hereditas. 2023 Oct 31;160 (1) :36.|Hereditas. 2025 Aug 14;162 (1) :158.|Hereditas. 2025 Aug 25;162 (1) :170.|Hum Cell. 2025 Apr 18;38 (3) :91.|Hum Gene Ther. 2024 Sep;35 (17-18) :695-709.|Hum Immunol. 2025 Aug 19;86 (5) :111566.|In Silico Research in Biomedicine 2025 Nov 6;1:100116.|Inorganica Chim Acta. 468 (2017) 270-279.|Int Immunopharmacol. 2021 Dec;101 (Pt A) :108264.|Int Immunopharmacol. 2024 May 10:134:112197.|Int Immunopharmacol. 2025 Feb 20:148:114141.|Int Immunopharmacol. 2025 Jul 25:163:115277.|Int J Biol Macromol. 2024 Jul 4:133652.|Int J Biol Macromol. 2025 Mar 26:142529.|Int J Biol Sci. 2021 Jul 25;17 (12) :3255-3267.|Int J Med Sci. 2021 Jan 1;18 (2) :325-334.|Int J Med Sci. 2024 Jul 8;21 (9) :1769-1782.|Int J Mol Med. 2025 Jan;55 (1) :10.|Int J Mol Sci. 2019 Mar 5;20 (5) . pii: E1125. |Int J Mol Sci. 2022 Nov 19;23 (22) :14385.|Int J Mol Sci. 2023 Dec 25;25 (1) :312.|Int J Mol Sci. 2024 Mar 7;25 (6) :3101.|Int J Mol Sci. 2024 Nov 18;25 (22) :12376.|Int J Mol Sci. 2025 Aug 23;26 (17) :8201.|Int J Mol Sci. 2025 Jan 6;26 (1) :412.|Int J Nanomedicine. 2024 Dec 28:19:14059-14074.|Int J Nanomedicine. 2024 Jan 6:19:171-188.|Int J Nanomedicine. 2024 Jul 3:19:6717-6730.|Int J Oncol. 2023 Mar;62 (3) :39.|Int J Pharm. 2022 May 25;620:121761.|Int J Pharm. 2023 Mar 25:635:122779.|Int J Pharm. 2024 Mar 25:653:123894.|Int J Radiat Oncol Biol Phys. 2023 Feb 1;115 (2) :440-452.|Iran J Med Sci. 2024 Apr 30.|J Adv Res. 2025 Oct 16:S2090-1232 (25) 00818-5.|J Agric Food Chem. 2025 Jul 30;73 (30) :18822-18840.|J Biochem Mol Toxicol. 2022 Apr 25:e23077.|J Biomater Sci Polym Ed. 2018 Aug;29 (12) :1482-1497. |J Biomater Sci Polym Ed. 2021 Jun;32 (9) :1107-1124.|J Bone Oncol. 2021 Sep 20:30:100391.|J Cardiovasc Transl Res. 2021 Apr;14 (2) :355-364.|J Cell Biol. 2023 Jan 2;222 (1) :e202202110.|J Cell Mol Med. 2025 Jan;29 (1) :e70339.|J Cell Mol Med. 2025 Jan;29 (2) :e70358.|J Cell Mol Med. 2025 Jan;29 (2) :e70360.|J Cell Mol Med. 2025 Nov;29 (21) :e70928.|J Cell Physiol. 2021 Nov;236 (11) :7565-7577.|J Clust Sci. 2025 Nov 16;36 (6) :229.|J Colloid Interface Sci. 2024 Jul 15:676:378-395.|J Colloid Interface Sci. 2024 Jun 23:674:500-512.|J Control Release. 2019 Jun 26;307:247-260. |J Control Release. 2022 Apr:344:26-38.|J Control Release. 2024 Nov 30:377:661-674.|J Control Release. 2025 Jan 8:379:45-58.|J Dairy Sci. 2025 Aug 6:S0022-0302 (25) 00600-9.|J Ethnopharmacol. 2022 Dec 5:299:115676.|J Ethnopharmacol. 2025 Feb 13:119463.|J Exp Clin Cancer Res. 2024 Dec 26;43 (1) :330.|J Extracell Vesicles. 2022 Aug;11 (8) :e12255.|J Hematol Oncol. 2021 Oct 29;14 (1) :178.|J Immunother Cancer. 2022 Aug;10 (8) :e004006.|J Inflamm Res. 2025 May 8:18:6049-6060.|J Med Chem. 2023 Jul 27;66 (14) :9537-9560.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|J Nanobiotechnology. 2023 Feb 10;21 (1) :50.|J Org Chem. 2021 Oct 1;86 (19) :13360-13370.|J Pharmacol Sci. 2025 Jun;158 (2) :84-94.|J Transl Med. 2021 Mar 21;19 (1) :117.|J Transl Med. 2024 Dec 3;22 (1) :1095.|J Transl Med. 2025 Aug 12;23 (1) :900.|J Transl Med. 2025 Feb 28;23 (1) :247.|J Transl Med. 2025 Jan 2;23 (1) :1.|J Virol. 2021 Jul 26;95 (16) :e0076021.|Journal of New Chinese Medicine. 2016 (7) :278-282.|Lab Chip. 2025 Jul 23;25 (15) :3682-3693.|Lett Appl Microbiol. 2022 Sep;75 (3) :655-666.|Life Sci. 2025 Feb 7:123452.|Macromol Res. 2025 Apr 23.|Mar Life Sci Technol. 2025 May 12.|Mater Chem Phys. 2021, 124596.|Mater Today Bio. 2023 Aug 29:22:100780.|Mater Today Bio. 2025 Aug 16:34:102209.|Mater Today Chem. March 2022, 100637.|Med Oncol. 2025 Jul 21;42 (8) :358.|MedComm (2020) . 2021 Jun 3;2 (3) :467-480.|Mol Cancer. 2024 Jan 10;23 (1) :12.|Mol Cancer. 2024 May 9;23 (1) :83.|Mol Carcinog. 2021 Jun;60 (6) :413-426.|Mol Cell Biochem. 2021 Feb;476 (2) :1233-1243.|Mol Med Rep. 2020 Aug;22 (2) :915-925.|Mol Med Rep. 2025 Sep;32 (3) :237.|Mol Nutr Food Res. 2024 May 29:e2400123.|Mol Ther. 2019 May 8;27 (5) :1051-1065. |Nanoscale Adv. 2025 Aug 8;7 (17) :5421-5434.|Nanoscale Res Lett. 2018 Nov 3;13 (1) :350. |Nanotheranostics. 2021 Jan 1;5 (2) :143-154.|Nanotheranostics. 2021; 5 (2) : 143-154.|Nat Cell Biol. 2020 Sep;22 (9) :1056-1063.|Nat Cell Biol. 2024 Aug;26 (8) :1346-1358.|Nat Commun. 2018 Oct 8;9 (1) :4139. |Nat Commun. 2023 Apr 13;14 (1) :2109.|Nat Commun. 2024 Jul 9;15 (1) :5761.|Nat Commun. 2025 Aug 7;16 (1) :7308.|Nat Commun. 2025 Feb 1;16 (1) :1241.|Nat Commun. 2025 Feb 4;16 (1) :1327.|Nat Commun. 2025 Jan 31;16 (1) :1212.|Nat Commun. 2025 May 7;16 (1) :4224.|Nat Med. 2016 May;22 (5) :547-56. |Nat Prod Commun. 2024 Mar 20.|Nat Protoc. 2021 Jan;16 (1) :405-430.|Nature. 2023 Jun;618 (7964) :374-382.|Nature. 2024 Oct;634 (8036) :1229-1237.|Neuropharmacology. 2024 Aug 15:254:109981.|NPJ Breast Cancer. 2022 May 6;8 (1) :60.|Oncogene. 2022 Jul;41 (31) :3846-3858.|Oncogene. 2025 Sep;44 (34) :3096-3112.|Oncotarget. 2017 Nov 24;8 (67) :111190-111212. |Oxid Med Cell Longev. 2022 Apr 5;2022:4740931.|Oxid Med Cell Longev. 2023 Jan 14:2023:9966355.|Patent. US20180185310A1.|Patent. US20180185346A1.|Patent. US20180185379A1.|Patent. US20180185386A1.|Patent. US20180185387A1.|Patent. US20180185388A1|Patent. US20180185389A1.|Patent. US20180193355A1.|Patent. US20200085841A1 |Patent. US20200345752A1.|Patent. US20210275477A1.|Patent. US20220016148A1.|Patent. US20230190773A1.|Patent. US20240245665A1.|Patent. US20240344035A1|Patent. US20240344035A1.|Patent. US20240352093A1|Patent. US20250129329A1.|Pathol Res Pract. 2022 Jan:229:153735.|Pathol Res Pract. 2025 Oct 15:276:156272.|Pharm Res. 2025 Jan;42 (1) :137-149.|Pharmaceuticals (Basel) . 2025 May 16;18 (5) :733.|Pharmaceutics. 2024 Nov 25;16 (12) :1516.|Pharmaceutics. 2025 Jul 25;17 (8) :967.|Pharmacol Res. 2021 Jul:169:105642.|Pharmacol Res. 2024 May 9:204:107208.|Phytochemistry. 2021 Oct:190:112892.|Phytomedicine. 2022 May:99:153964.|Phytomedicine. 2023 Aug:117:154922.|Phytomedicine. 2023 Jun:114:154752.|Phytomedicine. 2024 Dec:135:156155.|Phytomedicine. 2024 Sep 13:135:156051.|Phytomedicine. 2025 Jun 12:145:156981.|Phytomedicine. 2025 Nov 22:150:157584.|Phytomedicine. 2025 Nov:147:157220.|Phytother Res. 2025 Jul;39 (7) :3241-3253.|PLoS Pathog. 2020 Mar 24;16 (3) :e1008429.|Polym Bull (Berl) . 30 September 2022.|Preprints. 2025 Sep 4.|Redox Biol. 2021 Oct:46:102120.|Res Sq. 2024 Dec 5:rs.3.rs-5278203.|Res Sq. 2024 Jul 11.|Res Sq. 2024 Sep 11.|Res Sq. 2025 Jul 26.|Res Sq. 2025 Sep 12.|Research Square Preprint. 2020 Jul.|Research Square Preprint. 2021 Nov.|Research Square Preprint. 2021 Sep.|Research Square Preprint. 2023 Nov 25.|Research Square Preprint. 2023 Sep 20.|Research Square Preprint. 2024 Aug 08.|RSC Adv. 2025 Jun 16;15 (26) :20385-20396.|Sci Adv. 2023 Mar 10;9 (10) :eadd8539.|Sci Adv. 2025 Aug 15;11 (33) :eadu2906.|Sci Bull. 2025 Sep 29:S2095-9273 (25) 00984-3.|Sci Rep. 2025 Jul 1;15 (1) :22067.|Sci Rep. 2025 Mar 5;15 (1) :7704.|Sci Rep. 2025 May 30;15 (1) :18978.|Sci Rep. 2025 Oct 16;15 (1) :36227.|Sci Signal. 2024 Nov 26;17 (864) :eadp1375.|Sci Transl Med. 2024 Apr 3;16 (741) :eadj5705.|Shock. 2023 Jul 1;60 (1) :100-109.|Signal Transduct Target Ther. 2023 Feb 3;8 (1) :51.|Signal Transduct Target Ther. 2024 Oct 16;9 (1) :273.|Small. 2023 May;19 (21) :e2205606.|Small. 2024 Jun;20 (25) :e2308265.|SSRN. 2023 Aug 14.|SSRN. 2023 Nov 28.|SSRN. 2025 Mar 4.|Ther Deliv. 2017 Mar;8 (5) :249-264.|Theranostics. 2020 May 17;10 (15) :6581-6598. |Thyroid. 2019 Jun;29 (6) :809-823. |TMR Modern Herbal Medicine. 2021 Jul.|Toxicol Appl Pharmacol. 2024 Aug 30:117082.|Toxicol Appl Pharmacol. 2025 Feb 4:117261.|Transl Androl Urol. Jul 29, 2022.|Transl Oncol. 2022 Jan;15 (1) :101272.|Ulsan National Institute of Science and Technology. 2023 Aug.|Universiti Tunku Abdul Rahman. 2023 Sep 11.|University of Arizona. 2025.|University of Bonn. 2025 Feb.|University of Delaware. 2025.|University of Gothenburg. 2023 Jun 27.|University of Granada. 2025.|University of Szeged. Department of Biochemistry and Molecular Biology Faculty of Science and Informatics. 2020 Nov.|World J Acupunct Moxibustion. 2025 Jul 23.

• CAS Number:

  [23214-92-8]